Early access of TMC114 in combination with low-dose ritonavir RTV and other antiretrovirals ARVs in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - TMC114-C226
- Conditions
- HIVMedDRA version: 6.1Level: HLTClassification code 10052740
- Registration Number
- EUCTR2005-002437-13-IT
- Lead Sponsor
- TIBOTEC PHARMACEUTICALS LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15000
Inclusion Criteria
n.a.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
n.a.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Early access to TMC114 in highly treatment experienced with limited to no treatment options;Secondary Objective: Data of safety and tolerability of TMC 114 in combination with Ritonavir rtv and other ARV;Primary end point(s): n.a.
- Secondary Outcome Measures
Name Time Method